Alzamend Neuro, Inc.
ALZNAlzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, with a primary emphasis on Alzheimer's disease.
Earnings
Next report
Sep 9, 2026 (In 1 week)Competitors
By market cap
By revenue growth
By net margin
Profile
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, with a primary emphasis on Alzheimer's disease. The company's core value proposition centers on advancing therapeutic treatments from research stages through clinical development to address significant unmet medical needs in brain health.
Alzamend Neuro is a clinical-stage developer competing against established pharmaceutical firms and specialized biotech companies in the highly competitive Alzheimer's and neurodegenerative treatment market.
FAQ
- What is Alzamend Neuro, Inc.'s market cap?
- Alzamend Neuro, Inc. (ALZN) has a market capitalization of $8.1M and trades on NASDAQ.
- Who are Alzamend Neuro, Inc.'s competitors?
- Alzamend Neuro, Inc.'s key competitors include Biogen Inc., Eli Lilly and Company, Acumen Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Alzamend Neuro, Inc. partner with?
- Alzamend Neuro, Inc.'s notable partners include Hyperscale Data, Inc., Ault Lending, LLC, Ault & Co..
- Where is Alzamend Neuro, Inc. headquartered?
- Alzamend Neuro, Inc. is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2021.